NCT03848962 Collection and Distribution of Biospecimens for Novel Research Uses
| NCT ID | NCT03848962 |
| Status | Recruiting |
| Phase | — |
| Sponsor | iSpecimen Inc |
| Condition | Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2016-06-30 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2016-06-30 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively "research").
Eligibility Criteria
Inclusion Criteria: * Individual is developmentally aged 7 years old and above for RUO collections (only) * Individual meets requirements of a current request for research materials from iSpecimen * If a blood collection will be performed as part of the screening process or RUO collection, the individual's health will be assessed by medical staff through medical record review, clinical exam, and/or the review of an updated medical history as provided by the participant * Individual has reviewed and signed a consent form for an RUO specimen collection if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf. * Individual has reviewed and signed a consent form for remnant specimen usage in research if required as part of the research or if a minor or a person with diminished decision-making capacity, their parent/guardian or Legally Authorized Representative has reviewed and signed the consent form on their behalf Exclusion Criteria: * Subjects that do not meet the inclusion criteria outlined above.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT03848962 clinical trial?
This trial is open to participants of all sexes, aged 1 Month or older, up to 89 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03848962 currently recruiting?
Yes, NCT03848962 is actively recruiting participants. Contact the research team at ehubbard@ispecimen.com for enrollment information.
Where is the NCT03848962 trial being conducted?
This trial is being conducted at Huntsville, United States, Lexington, United States.
Who is sponsoring the NCT03848962 clinical trial?
NCT03848962 is sponsored by iSpecimen Inc. The trial plans to enroll 10,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.